

## Highly Specialised Technology Committee Interests Register

**Topic: Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Ed Wilson	HST Committee Member	Non-Financial Professional Interest	Professor Wilson directs PenTAG, the EAG that critiqued the industry submission for fosdenopterin but was not involved in the analysis.	15/08/2024	It was agreed that Professor Wilson would be partially excluded i.e. able to participate in discussions but will not be voting or making recommendations
Emtiyaz Chowdhury	HST Committee Member	Non-Financial Professional Interest	Mr Chowdhury is employed by Parexel. Parexel is a CRO that provides services to industry. He has not been directly involved with any work related to this technology.	15/08/2024 07/11/2024	It was agreed that Mr Chowdhury's declaration would not prevent him from participating in discussions on this evaluation.
Bernd Schwahn	Clinical expert	Direct Financial & Non-Financial Interests	<ul style="list-style-type: none"> <li>In 2019 Mr Schwahn has received a fee and travel expenses from Origin BioSciences for one day of attendance at a key opinion leader meeting in London</li> <li>Mr Schwahn has been an unpaid investigator for clinical</li> </ul>	15/08/2024	It was agreed that Mr Schwahn's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>trials sponsored by Alexion and by Origin Biosciences from 2013 to 2022.</p> <ul style="list-style-type: none"> <li>Mr Schwahn's organisation received an unconditional educational grant from Origin Biosciences to organise a medical scientific workshop in 2021.</li> <li>Mr Schwahn has authored and co-authored publications about the clinical use of cPMP.</li> </ul>		